Jeffrey M. Johnston
Nessuna posizione attualmente
Storia della carriera di Jeffrey M. Johnston
Precedenti posizioni note di Jeffrey M. Johnston
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 01/09/2005 | 01/01/2016 |
| RA PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2016 | - |
| GSK PLC | Corporate Officer/Principal | - | - |
Triangle Pharmaceuticals, Inc.
 Triangle Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Triangle Pharmaceuticals Inc. provided antiviral drug candidates for the human immunodeficiency virus. The company was founded in 1995 and was located in Durham, NC. | Direttore Tecnico/Scientifico/R&S | - | - |
| Critical Therapeutics, Inc. | Direttore Tecnico/Scientifico/R&S | 20/06/2011 | - |
| Corporate Officer/Principal | - | 20/06/2011 |
Formazione di Jeffrey M. Johnston
| Davidson College | Undergraduate Degree |
| Duke University School of Medicine | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 7 |
| Regno Unito | 2 |
Posizioni
| Chief Tech/Sci/R&D Officer | 4 |
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 5 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| IRONWOOD PHARMACEUTICALS, INC. | Health Technology |
| GSK PLC | Health Technology |
| Aziende private | 3 |
|---|---|
| Critical Therapeutics, Inc. | Health Technology |
Triangle Pharmaceuticals, Inc.
Triangle Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Triangle Pharmaceuticals Inc. provided antiviral drug candidates for the human immunodeficiency virus. The company was founded in 1995 and was located in Durham, NC. | Commercial Services |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Jeffrey M. Johnston
- Esperienza
